| Literature DB >> 17960923 |
Williams Porcal1, Paola Hernández, Mariana Boiani, Gabriela Aguirre, Lucía Boiani, Agustina Chidichimo, Juan J Cazzulo, Nuria E Campillo, Juan A Paez, Ana Castro, R Luise Krauth-Siegel, Carolina Davies, Miguel Angel Basombrío, Mercedes González, Hugo Cerecetto.
Abstract
New benzofuroxans were developed and studied as antiproliferative Trypanosoma cruzi agents. Compounds displayed remarkable in vitro activities against different strains, Tulahuen 2, CL Brener and Y. Its unspecific cytotoxicity was evaluated using human macrophages being not toxic at a concentration at least 8 times, and until 250 times, that of its T. cruzi IC50. Some biochemical pathways were studied, namely parasite respiration, cysteinyl active site enzymes and reaction with glutathione, as target for the mechanism of action. Not only T. cruzi respiration but also Cruzipain or trypanothione reductase were not affected, however the most active derivatives, the vinylsulfinyl- and vinylsulfonyl-containing benzofuroxans, react with glutathione in a redox pathway. Furthermore, the compounds showed good in vivo activities when they were studied in an acute murine model of Chagas' disease. The compounds were able to reduce the parasite loads of animals with fully established T. cruzi infections.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17960923 DOI: 10.1021/jm070604e
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446